At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ADIL Adial Pharmaceuticals
Market Closed 11-22 16:00:00 EST
1.01
-0.01
-0.98%
盘后0.9999
-0.01-1.00%
19:57 EST
High1.02
Low0.9900
Vol149.48K
Open1.02
D1 Closing1.02
Amplitude2.94%
Mkt Cap6.47M
Tradable Cap6.35M
Total Shares6.41M
T/O149.95K
T/O Rate2.38%
Tradable Shares6.29M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Adial Pharmaceuticals Advances AD04 with Promising Study Results
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.